GM V8 Failures After Recall Repairs Prompt Probe of 997,743 Vehicles

Federal safety regulators are examining reported failures of General Motors’ 6.2-liter V8 after recall remedies, expanding the inquiry to 997,743 model-year 2021-2026 trucks and SUVs. The central question is no longer limited to the engines covered by GM’s original manufacturing window: investigators are also evaluating reports involving later-built engines and vehicles that had already received an oil change or complete engine replacement.

The National Highway Traffic Safety Administration upgraded the proceeding to Engineering Analysis EA26005 on August 20, 2026. The affected engine, identified by GM as the L87, is installed in the Cadillac Escalade, Chevrolet Tahoe and Suburban, GMC Yukon, Chevrolet Silverado 1500 and GMC Sierra 1500. According to details of the expanded federal investigation, regulators will assess post-recall failures and the effectiveness of GM’s remedies.

Two documented manufacturing problems

GM’s earlier recall covered 597,630 U.S. vehicles and identified an elevated failure rate among L87 engines built from March 1, 2021, through May 31, 2024. The recall population included 79,747 Cadillac Escalades.

The filing identified two manufacturing-related problems: sediment contamination capable of damaging connecting-rod bearings, and crankshafts produced outside specification with an improper surface finish. Either condition concerns critical internal engine components. Damage at the bearings or crankshaft can progress to complete engine failure, potentially causing a loss of motive power in traffic.

GM’s remedy depended on the result of a dealer inspection. Engines that failed the inspection were replaced at no cost rather than rebuilt. Vehicles that passed received higher-viscosity oil, along with a replacement oil filter and oil-fill cap.

That branching remedy makes inspection accuracy and remedy durability central to the engineering analysis. Regulators must determine whether the inspection reliably distinguished engines requiring replacement from those for which the oil-related remedy was adequate. They must also establish whether reported later failures arose from the defects described in the recall, another condition, or unrelated causes. Complaint totals alone cannot answer those questions.

Post-remedy reports widen the reliability question

NHTSA’s Office of Defects Investigation received 499 complaints alleging engine failure after a recall remedy. Of the cases categorized by the office, 473 involved vehicles that had received the oil-viscosity change and 26 involved vehicles that had received complete replacement engines. GM separately reported receiving 6,953 complaints of failures following a remedy.

The expanded analysis also documents 191 reported failures involving engines built after May 31, 2024, the end of the production period identified in the original recall. Those reports explain why the potential population has grown to nearly one million vehicles, but they are not a final determination that all later engines share the original defects.

The 26 reports following complete engine replacement require similarly careful treatment. They establish a reason for regulators to investigate replacement outcomes, but they do not by themselves demonstrate that replacement engines retained the same manufacturing conditions. NHTSA will need to evaluate engine build information, inspection records, remedy histories and the physical evidence from failed units before drawing a causal conclusion.

An owner of a 2024 Escalade separately reported that the vehicle shut down at 70 mph with 32,000 miles and was subsequently diagnosed by Cadillac with total engine failure. Cadillac reportedly ordered a replacement engine. That account has not been independently verified, but it illustrates the operational concern behind the inquiry: an engine shutdown can remove motive power with little warning.

A completed recall does not close the engineering case

Recall completion records show that a prescribed action was performed; they do not, by themselves, prove long-term reliability. For a remedy involving inspection thresholds and different repair paths, effectiveness must be assessed against what happens afterward. That includes whether passing engines remain serviceable, whether replacement engines perform as intended and whether the original production cutoff captures the full affected population.

The investigation remains open, and neither the complaints nor the individual owner reports constitute a final agency finding that GM’s remedies are defective. The next decisive step is whether NHTSA can connect the reported post-remedy and later-production failures to a common, documented mechanism. Until that analysis is complete, the original recall’s production boundary and the durability of both remedy paths remain unresolved.

By Thomas Caldwell — AMI’s senior editor for mechanical and mobility engineering, covering vehicle electronics, systems integration, electrification, chassis systems, propulsion, and safety policy.